Talquetamab Combination Therapy for Multiple Myeloma
(MonumenTAL-2 Trial)
Trial Summary
What is the purpose of this trial?
The purpose of this study is to characterize the safety and tolerability of talquetamab when administered in different combination regimens and to identify the safe dose(s) of talquetamab combination regimens.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the drug Talquetamab for treating multiple myeloma?
Is Talquetamab safe for humans?
What makes the drug Talquetamab unique for treating multiple myeloma?
Research Team
Janssen Research & Development, LLC Clinical Trial
Principal Investigator
Janssen Research & Development, LLC
Eligibility Criteria
This trial is for individuals with confirmed multiple myeloma who can follow the study's lifestyle restrictions, including pregnancy prevention plans. They must have measurable disease indicators and be in good physical condition (ECOG score of 0 or 1). Women of childbearing potential need a negative pregnancy test before starting treatment.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive talquetamab in combination with other anticancer therapies to assess safety and tolerability
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Talquetamab
Talquetamab is already approved in United States, European Union for the following indications:
- Relapsed or refractory multiple myeloma
- Relapsed or refractory multiple myeloma
Find a Clinic Near You
Who Is Running the Clinical Trial?
Janssen Research & Development, LLC
Lead Sponsor
Giacomo Salvadore
Janssen Research & Development, LLC
Chief Medical Officer since 2023
MD from the University of Rome, Tor Vergata
Ricardo Attar
Janssen Research & Development, LLC
Chief Executive Officer since 2008
PhD in Molecular Biology from the University of Buenos Aires